60 degrees pharmaceuticals unveils name of chronic babesiosis clinical trial: b-free chronic babesiosis study

Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competition a $5k donation from the company was split between iladef and gla to recognize the winning name b-free, a phase 2 trial, will commence in early november and run for approximately 12 months washington, oct. 09, 2025 (globe newswire) --  60 degrees pharmaceuticals, inc. (nasdaq: sxtp; sxtpw) (“60 degrees pharma” or the “company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today the name of its chronic babesiosis trial is the b-free chronic babesiosis study. the b-free study (nct06656351), the first in the world to evaluate a potential new therapeutic for chronic babesiosis, will run for approximately 12 months.
SXTP Ratings Summary
SXTP Quant Ranking